Abstract
Bacteriala nd clinical experimentsf or ophthalmicu se of clindamycin-palmitate (C LDM-palm.) were performed and following results were obtained.
1) There was almost no bacteriostatic effect of CLDM-palm. against major causative organisms of ocular infections. CLDM showed a strong antibacterial activity against gram-positive cocci.
2) Minimum growth inhibitory concentration of CLDM-palm. was higher than 25 mcg/ml for 50 strains of Staphylococcus aureus isolated from the patients; meanwhilet hat of CLDM was lower than ≤0.19 mcg/ml for 92% of strains. Therefore it was proved that CLDM showed high sensitivity against S. aureus.
3) After oral administration of 100 mg/kg of CLDM-palm. to the rabbits, the concentration in the aqueous humor attained the peak after 3 hours, and remained relatively high level after 6 hours. After 2 hours the ocular tissue concentration showed the maximum level in the iris and ciliary body, then the eyelid, the conjunctiva, the extraocular muscles, the retina and choroid in order of decreasing concentration.
4) The concentration in the human eyelid revealed in the high level at 2 hours after administration of CLDM-palm.
5) The oral application of CLDM-palm. 100 mg/kg/day, against suppurative ocular infection revealed excellent effects in all of 2 cases with acute catarrhal conjunctivitis, 4 of 6 cases withh ordeolum externum, 3 of 4 cases with hordeolum internum, a case of lid abscess, one of 2 cases with dacryocystitis neonatorum and a case of idiopathic panophthalmitis.
Post-operative infection was prevented in all of 10 cases by the oral administration of CLDM-palm. 10-20 mg/kg/day.
6) Side effects: A case out of 26 cases complained diarrhoea, and was able to be treated continuously by the drug. These symptom immediately disappeared after cessation of the drug.
No other side effect was found in the other cases.
